These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34263141)

  • 1. Next-generation cytokines for cancer immunotherapy.
    Xue D; Hsu E; Fu YX; Peng H
    Antib Ther; 2021 Apr; 4(2):123-133. PubMed ID: 34263141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines that target immune killer cells against tumors.
    Qiao J; Fu YX
    Cell Mol Immunol; 2020 Jul; 17(7):722-727. PubMed ID: 32523115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
    Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
    Wang Y; Zhang H; He YW
    Front Immunol; 2019; 10():1574. PubMed ID: 31379815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
    Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
    BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
    Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
    Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
    Ishihara J; Ishihara A; Sasaki K; Lee SS; Williford JM; Yasui M; Abe H; Potin L; Hosseinchi P; Fukunaga K; Raczy MM; Gray LT; Mansurov A; Katsumata K; Fukayama M; Kron SJ; Swartz MA; Hubbell JA
    Sci Transl Med; 2019 Apr; 11(487):. PubMed ID: 30971453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine engineering for targeted cancer immunotherapy.
    Bonati L; Tang L
    Curr Opin Chem Biol; 2021 Jun; 62():43-52. PubMed ID: 33684633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns.
    Yamamoto T; Kimura T; Ueta E; Tatemoto Y; Osaki T
    Oncology; 2003; 64(4):407-15. PubMed ID: 12759539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in engineering and delivery strategies for cytokine immunotherapy.
    Bohmer M; Xue Y; Jankovic K; Dong Y
    Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity.
    Hu P; Mizokami M; Ruoff G; Khawli LA; Epstein AL
    Blood; 2003 Jun; 101(12):4853-61. PubMed ID: 12609842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of Interleukin-2 family cytokines in tumor immunotherapy research.
    Zhou Y; Quan G; Liu Y; Shi N; Wu Y; Zhang R; Gao X; Luo L
    Front Immunol; 2023; 14():1090311. PubMed ID: 36936961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.